Uncategorized

One hospital has piloted the program for a few months and seen some early successes that have made other operators interested, an Aetna spokesperson said.

Johnson & Johnson, which said it made the decision based on a market assessment, did not specify the markets it is leaving or provide a timeline.

Research funded by the Agency for Healthcare Research and Quality found insufficient evidence to determine the accuracy — or possible harm — of the cancer screenings.

Olympus is recalling certain lots of needles, used for lung cancer biopsy, because components can detach during procedures.

The take-private deal should give Premier more capital to bolster its operations and invest in technology.

While last week’s recommended changes by CDC advisors to the MMRV vaccine schedule are unlikely to have a tangible effect on Merck’s business, the company said the removal of choice for healthcare providers is “concerning.”

The government submitted a 49-page brief urging the high court to affirm Trump’s broad emergency levies.

Recent changes to federal guidance for prescribing COVID-19 vaccinations have providers worried for what’s to come. “We have opened a door to not using science to guide care,” said one physician. 

Industry leaders should engage with state lawmakers on AI bills, given many legislators have limited experience in healthcare or AI, experts said at the HIMSS AI Leadership Strategy Summit.

An advisory committee last year found that Zynquista’s benefit-risk profile in type 1 diabetes was unfavorable due to cases of diabetic ketoacidosis.